THE Therapeutic Goods Administration has confirmed the implementation of a Priority Review pathway for the registration of novel prescription medicines for Australian patients, with a target timeframe for assessment of 150 days - up to 30 days shorter than standard registration processes.
Details now at www.tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Jun 17
